What We're Reading: Page 116
Industry reads hand-picked by our editors
May 25, 2022
-
Stat
Viruses on hiatus during Covid are back — and behaving in unusual ways
-
Axios
Washington once again targets prescription drug middlemen
-
Endpoints News
Moderna seeks to dismiss Alnylam suit over Covid-19 vaccine component, claiming wrong venue
-
PharmaVoice
First 90 Days: Syneos Health's Michelle Keefe
May 24, 2022
-
The Wall Street Journal
Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
-
Reuters
China Junshi's potential COVID drug shows promise in small trial
-
FierceBiotech
Genocea closes up shop after cash reserves dry up
May 23, 2022
May 20, 2022
-
STAT
CDC advisory committee recommends Covid boosters for kids ages 5 to 11
-
The Boston Globe
This startup aims to make contraceptives that prolong fertility, delay menopause, and improve women’s health
-
Endpoints News
Flagship’s Foghorn, partnered with Merck and Eli Lilly, gets a partial FDA hold after patient death
May 19, 2022
-
Evaluate Vantage
Investors bite the big pharma hands that feed them
-
Bloomberg
Insiders Bemoan Culture, Data Gaps That Limit CDC in Crises
-
The Wall Street Journal
Drugmaker Endo Begins Debt-Restructuring Talks With Creditors Amid Opioid Litigation
-
Stat
U.S. monkeypox case reported, as Spain, Portugal report infections in growing outbreak
May 18, 2022
-
The Wall Street Journal
Cerebral Board Members Agree to Replace CEO Amid Federal Probe Into Prescription Practices
-
Bloomberg
Where Are the Paxlovid Combination Trials?
-
Endpoints News
Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm
-
C&EN
New day for antibody-drug conjugates
May 17, 2022
-
The Wall Street Journal
Pfizer's Covid-19 Booster Cleared for 5- to 11-Year-Olds
-
The New York Times
Targeting the Uneven Burden of Kidney Disease on Black Americans
-
Reuters
AstraZeneca boosts COVID portfolio with RQ Bio deal
-
FiercePharma
GlaxoSmithKline is no more: Meet the scaled down 'GSK'
Previous
